The Cancer Drug Development Forum (CDDF) Annual Conference is a prestigious event that unites leaders in the field of oncology drug development. Scheduled from 5th to 7th February 2024, this conference will offer a hybrid format, allowing participants to attend either in person or virtually. The event brings together medical researchers, pharmaceutical industry representatives, regulatory authorities, health technology assessment agencies and patient advocacy groups for engaging discussions and networking opportunities.
- Explore and analyze innovative approaches to accelerate oncology drug development, considering the changing paradigms and regulatory environment in the field.
- Understand the impact of recent and forthcoming regulatory changes on the development and approval of oncology drugs.
- Examine the use of real-world evidence and its significance in shaping future oncology care.
- Discuss decentralized care and clinical trial strategies, drawing from lessons learned during the COVID-19 pandemic.
- Evaluate the potential of drug and biomarker combinations and their regulatory acceptance.
- Address challenges and opportunities in utilizing companion diagnostics in oncology drug development and learnings from the IVDR.
- Discover advancements in master protocols, platform trials, and blood-based biomarkers for early patient testing.
- Engage in forward-facing discussions on the future of global regulatory collaborations in oncology drug development.
Day 1: Real World Evidence and reflections from CDDF activities on 2023 to advance oncology drug development
- Keynote Address: Real-World Evidence in Shaping Oncology Care: Case Studies, industry, patients, CHMP and FDA Insights
- Learnings from 2023 CDDF conferences to accelerate oncology drug developments
Day 2: Decentralized Care and Clinical Trials
- Learnings from COVID-19: Adapting Clinical Trials for Decentralized Care.
- Patient Perspective: Enhancing Safety and Diversity in clinicalTrials.
- Accelerating Drug Development: Discuss Paradigms to Accelerate Oncology Drug Development with regulators, academics, industry, and payers.- Panel Discussion on the Impact of Recent Regulatory Changes in Oncology
Day 3: Drug and Biomarker Combinations in Oncology
- Novel-Novel Combinations: Regulatory Acceptance and Dose Optimization.
- Challenges and Opportunities with Companion Diagnostics in Drug Development, with shared learnings from IVDR.
- Advancements in Master Protocols, Platform Trials, and Early Patient Testing.
- The Future of Global Regulatory Collaborations in Oncology.
The hybrid format of the conference offers participants the flexibility to network in person or virtually. Attendees can connect with peers, speakers, and industry experts through face-to-face interactions and interactive discussions. The conference provides a platform to exchange ideas, share experiences, and build valuable connections within the oncology drug development community.
Join us at the CDDF Annual Conference 2024 to be part of the forefront in accelerating oncology drug development and making a lasting impact on the lives of cancer patients. Together, we can drive positive change and innovation in the fight against cancer.